The clinical significance of<i>BRAF</i>and<i>NRAS</i>mutations in a clinic-based metastatic melanoma cohort

Abstract

We were able to confirm the effect of BRAF inhibitor treatment in a single clinical institution. The results suggest further that BRAF mutation is a weak prognostic factor but a strong predictive factor and that BRAF-mutant melanoma might constitute one or more distinct subtypes of the disease with certain aetiology and clinical outcome.